EFFECT OF COMPLEMENT FACTOR 5A RECEPTOR 1 (C5AR1) ANTAGONIST ACT-1014-6,470 ON THE CYTOCHROME P450 2C19 AND 3A4 SUBSTRATES OMEPRAZOLE AND MIDAZOLAM IN A COCKTAIL STUDY IN HEALTHY SUBJECTS

被引：0
|
作者：
Anliker-Ort, S. M. [1 ,2 ]
Berger, B. [1 ]
Kaufmann, P. [1 ]
Jana, L. [3 ]
van den Anker, J. [4 ]
Dingemanse, J. [1 ]
机构：
[1] Idorsia Pharmaceut, Allschwil, Switzerland
[2] Univ Childrens Hosp, Basel, Switzerland
[3] CEPHA Sro, Plzen, Czech Republic
[4] Univ Basel Childrens Hosp, Basel, Switzerland
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2023年 / 113卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-054
引用
收藏
页码：S61 / S62
页数：2
相关论文
共 32 条
  • [1] ASCPT Abstract PII-054: Effect of Complement Factor 5A Receptor 1 (C5AR1) Antagonist ACT-101-6450 on the Cytochrome P450 2C19 and 3A4 Substrates Omeprazole and Midazolam in a Cocktail Study in Healthy Subjects (vol 113, pg S5, 2023)
    Janu, L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 114 (03) : 721 - 721
  • [2] Evaluation of the cytochrome P450 2C19 and 3A4 inhibition potential of the complement factor 5a receptor 1 antagonist ACT-1014-6470 in vitro and in vivo
    Anliker-Ort, Marion
    Dingemanse, Jasper
    Delahaye, Stephane
    Janu, Lubos
    van den Anker, John
    Berger, Benjamin
    Kaufmann, Priska
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2023, 16 (07): : 1220 - 1231
  • [3] EFFECT OF ACT-539313, A SELECTIVE OREXIN-1 RECEPTOR ANTAGONIST, ON THE CYTOCHROME P450 2C9, 2C19, AND 3A4 SUBSTRATES FLURBIPROFEN, OMEPRAZOLE, AND MIDAZOLAM USING A COCKTAIL APPROACH.
    Berger, B.
    Kaufmann, P.
    Berse, M.
    Grignaschi, N.
    Dingemanse, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S33 - S33
  • [4] Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects
    Darwish, Mona
    Kirby, Mary
    Robertson, Philmore, Jr.
    Hellriegel, Edward T.
    CLINICAL PHARMACOKINETICS, 2008, 47 (01) : 61 - 74
  • [5] Interaction Profile of Armodafinil with Medications Metabolized by Cytochrome P450 Enzymes 1A2, 3A4 and 2C19 in Healthy Subjects
    Mona Darwish
    Mary Kirby
    Philmore Robertson
    Edward T. Hellriegel
    Clinical Pharmacokinetics, 2008, 47 : 61 - 74
  • [6] Stereoselective Metabolism of Omeprazole by Cytochrome P450 2C19 and 3A4: Mechanistic Insights from DFT Study
    Jana, Kalyanashis
    Bandyopadhyay, Tusar
    Ganguly, Bishwajit
    JOURNAL OF PHYSICAL CHEMISTRY B, 2018, 122 (22): : 5765 - 5775
  • [7] First-in-human study with ACT-1014-6470, a novel oral complement factor 5a receptor 1 (C5aR1) antagonist, supported by pharmacokinetic predictions from animals to patients
    Ort, Marion
    Dingemanse, Jasper
    Hsin, Chih-hsuan
    Richard, Muriel
    Huehn, Eva
    Sabattini, Giancarlo
    van de Wetering, Jeroen
    Kornberger, Ruediger
    van den Anker, John
    Kaufmann, Priska
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2022, 131 (02) : 114 - 128
  • [8] PREDICTING KINETIC PARAMETERS KM AND VMAX FOR SUBSTRATES OF HUMAN CYTOCHROME P450 1A2, 2C9, 2C19, 2D6, AND 3A4
    Zhang, Jinhua
    Fraczkiewicz, Robert
    Bolger, Michael B.
    Waldman, Marvin
    Woltosz, Walter S.
    Enslein, Kurt
    DRUG METABOLISM REVIEWS, 2008, 40 : 119 - 119
  • [9] Cytochrome P450 inhibition screening: Validation of an HPLC-MS/MS method for CYP1A2, 2C9, 2C19, and 3A4/5 inhibition assessment
    Herron, William
    Pugnaghi, Franca
    DRUG METABOLISM REVIEWS, 2006, 38 : 49 - 50
  • [10] Cytochrome P450 1A1, 2C9, 2C19, and 3A4 Polymorphisms Account for Interindividual Variability of Toxicological Drug Metabolism in Cynomolgus Macaques
    Uno, Yasuhiro
    Uehara, Shotaro
    Murayama, Norie
    Yamazaki, Hiroshi
    CHEMICAL RESEARCH IN TOXICOLOGY, 2018, 31 (12) : 1373 - 1381
1234